Assembly Biosciences (ASMB) Curent Deferred Tax Liability (2014 - 2019)
Assembly Biosciences (ASMB) posted quarterly Curent Deferred Tax Liability of $3.3 million for Q1 2019, up 52.26% year-over-year from $2.1 million in Q1 2018, and little changed quarter-over-quarter from $3.3 million in Q4 2018.
Assembly Biosciences (ASMB) Curent Deferred Tax Liability (2014 - 2019) Analysis & Trends
Assembly Biosciences' Curent Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $3.3 million for Q1 2019.
- In Q1 2019, Curent Deferred Tax Liability rose 52.26% year-over-year to $3.3 million; the TTM figure through Mar 2019 stood at $3.3 million (up 52.26% YoY), while the FY2018 annual figure was $3.3 million, up 52.25% from the prior year.
- Curent Deferred Tax Liability for Q1 2019 stood at $3.3 million, roughly flat from $3.3 million in the prior quarter.
- The five-year high for Curent Deferred Tax Liability was $11.6 million in Q1 2015, with the low at $2.1 million in Q3 2018.
- The 5-year median for Curent Deferred Tax Liability is $11.1 million (2017), against an average of $8.3 million.
- The sharpest annual moves came in 2018 and 2019: Curent Deferred Tax Liability slumped 81.13% in 2018, then surged 52.26% in 2019.
- Assembly Biosciences' Curent Deferred Tax Liability stood at $11.6 million in 2015, then slipped by 4.14% to $11.1 million in 2016, then tumbled by 80.79% to $2.1 million in 2017, then surged by 52.25% to $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019.
- Business Quant data shows ASMB's Curent Deferred Tax Liability at $3.3 million in Q1 2019, $3.3 million in Q4 2018, and $2.1 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 3.25 Mn |
| Mar 31, 2019 | 3.25 Mn |
| Dec 31, 2018 | 3.25 Mn |
| Dec 31, 2018 | 3.25 Mn |
| Sep 30, 2018 | 2.11 Mn |
| Sep 30, 2018 | 2.11 Mn |
| Jun 30, 2018 | 2.11 Mn |
| Jun 30, 2018 | 2.11 Mn |
| Mar 31, 2018 | 2.14 Mn |
| Mar 31, 2018 | 2.14 Mn |
| Dec 31, 2017 | 2.14 Mn |
| Dec 31, 2017 | 2.14 Mn |
| Sep 30, 2017 | 11.15 Mn |
| Sep 30, 2017 | 11.15 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Mar 31, 2017 | 11.12 Mn |
| Mar 31, 2017 | 11.12 Mn |
| Dec 31, 2016 | 11.12 Mn |
| Dec 31, 2016 | 11.12 Mn |